Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

NanoVector Inc
Profile last edited on: 6/22/09      CAGE: 52FZ0      UEI:

Business Identifier: NO Business Identifier is currently available for this company.
Year Founded
2002
First Award
2008
Latest Award
2009
Program Status
Inactive
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

PO Box 98385
Raleigh, NC 27624
   (919) 878-8464
   info@nanovectorinc.com
   www.nanovectorinc.com
Location: Single
Congr. District: 02
County: Wake

Public Profile

NanoVector Inc is commercializing a patent pending nanoparticle drug delivery system developed at North Carolina State University (NCSU). NanoVector is seeking partnering opportunities to apply our technology to: * Extend the IP of existing drugs coming off of patent * Combine the NanoVector drug delivery technology with small molucule drug development programs to increase efficacy and/or specificity. * The encapsulation and delivery of unmodified oligonucleotides into a cell for gene silencing or into the cell nucleus for gene splicing. Effective targeted delivery of oligonucleotides is a critical technology enabler for RNAi therapeutics

Extent of SBIR involvement

User Avatar
Phase I Awards
2
Phase II Awards
0
Conversion Rate
0.00%
Phase I Dollars
$297,049
Phase II Dollars
$0
Total Awarded
$297,049

Synopsis: Awardee Business Condition

Employee Range
1-4
Revenue Range
Less than .5M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
N/A

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2009 1 NIH $200,000
Project Title: Multifunctional Therapeutics Using Engineered Plant Virus Nanoparticles
2008 1 NSF $97,049
Project Title: Cell Targeting Tool

Key People / Management

  Bruce J Oberhardt -- President

  Albert Bender

Company News

There are no news available.